Andrew Lewis
MD PhD FRCP
Principal Investigator
- BHF Intermediate Clinical Research Fellow; Radcliffe Department of Medicine
- Consultant Cardiologist (Honorary); Oxford Heart Centre
- Kemp Postdoctoral Fellow; Lincoln College Oxford
- EDI Champion; Oxford Centre for Clinical Magnetic Resonance Research
Spatial cardiology
Our group develops and applies advanced imaging techniques across various spatial scales, from subcellular to whole-heart, to better understand cardiovascular disease mechanisms, identify new therapeutic targets, and enhance early detection of treatment effects in experimental medicine trials. By integrating human cells, tissue samples, and non-invasive imaging of research and trial participants and patients, we aim to maximise the translational potential and mechanistic insights of our work. Current projects focus on metabolic and immunological pathways in heart failure, exploiting state-of-the-art spatial profiling techniques. We collaborate with a broad network of local, national, and international partners across academia and industry, and we welcome applicants with interdisciplinary expertise – please reach out to discuss current opportunities.
Andrew undertook doctoral research in translational cardiovascular imaging in the group of Professor Stefan Neubauer in Oxford. He was then appointed as a Clinical Lecturer in Oxford, prior to a post-doctoral fellowship at Massachusetts General Hospital in the laboratory of Professor Matthias Nahrendorf. Following award of a BHF Intermediate Clinical Fellowship, he was appointed as a Principal Investigator and Group Leader at the Radcliffe Department of Medicine and the Oxford BHF Centre for Research Excellence as well as Honorary Consultant Cardiologist at the Oxford Heart Centre. Andrew is a Fellow of the Royal College of Physicians of London, and the Kemp Postdoctoral Fellow at Lincoln College Oxford.
Recent publications
-
Multi-modal characterisation of cardiac function and electrophysiology in type 2 diabetes: a UK Biobank cross-sectional study
Preprint
Bertrand A. et al, (2024)
-
Modulating Cardiac Energetics in Cardio-Metabolic Syndromes: A mechanistic, hyperpolarized MR Trial of Ninerafaxstat Treatment
Preprint
Hundertmark MJ. et al, (2024)
-
The effect of sodium-glucose co-transporter 2 inhibitors on outcomes after cardiac resynchronization therapy.
Journal article
Bray JJH. et al, (2024), ESC Heart Fail
-
The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
Journal article
Buttice L. et al, (2024), Diabetes Obes Metab
-
The effect of bariatric surgery type on cardiac reverse remodelling.
Conference paper
Henry JA. et al, (2024), Int J Obes (Lond)